Clinical Data EHA26: BMS touts positive multiple myeloma data for two pipeline candidates Pharmaceutical TechnologyBMS shared Phase III data for mezigdomide and Phase I data for a CAR-T therapy at this year's EHA conference.OncologyRead full story pharminent June 17, 2026 (Last updated: June 17, 2026) Pharmaceutical Technology BMS shared Phase III data for mezigdomide and Phase I data for a CAR-T therapy at this year’s EHA conference. Oncology Read full story Post navigation Previous: FDA, Moderna appear aligned on mRNA flu shot heading into adcommNext: Altaris to acquire Simulations Plus in $375m all-cash deal Related Stories Clinical Data Novartis hit as Lp(a) drug fails cardio outcomes trial pharminent September 7, 2026 Clinical Data Major trial of Roche Alzheimer’s drug kicks off in Europe pharminent September 7, 2026 Clinical Data AbbVie’s T cell engager delivers survival benefit in Phase 3 multiple myeloma study pharminent September 4, 2026